Introduction
Osteosarcoma is a primary malignant tumor of bones that originates from mesenchymal tissue, frequently occurring in young adults and adolescents. 1 The 5-year survival rate without metastases for osteosarcoma patients has been increased from 10%-20% to 60%-70% due to the application of neoadjuvant chemotherapy. [2] [3] [4] [5] [6] Although neoadjuvant chemotherapy is effective in prolonging patient survival, 7, 8 it often results in the acquisition of drug resistance and the occurrence of side effects such as myelosuppression, toxicity of the kidneys, heart and nervous system, and gastrointestinal reactions. Therefore, it is necessary to develop molecule-targeted drugs with a good curative effect for patients with osteosarcoma.
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Zhang et al GRP78, also known as immunoglobulin heavy chain binding protein, is a molecular chaperone located in the endoplasmic reticulum (ER). It is a member of the 70 kDa heat shock (HSP70) protein family 9 and has the function of facilitating protein folding, assembly and transport, and regulating ER stress signaling. 10 During ER stress resulting from an external stimulus such as cytotoxic chemical stimulation, ultraviolet radiation, or cancers, cells initiate an unfolded protein response (UPR), which employs GRP78 as a necessary regulator to maintain the homeostasis of the ER. 11, 12 Recent studies showed that an overexpression of GRP78 was detected in several cancers such as hepatocellular carcinoma, 13 21 and ureter tumors. 22 Likewise, they showed that inhibiting expression of GRP78 can promote the apoptosis of tumor cells and slow down the growth and metastasis of tumor cells through their in vivo or in vitro experiments. Xia et al 23 reported that suppressing expression of GRP78 and Akt decreased P-gp expression and mitigated chemoresistance in human osteosarcoma. Our previous study similarly implied that there was a direct association between overexpression of GRP78 and osteosarcoma growth and metastasis. 24 Because of its importance for the survival of cancer cells, GRP78 could be used as an anticancer drug target.
Diallyl trisulfide (DATS) has been reported to possess anticancer activities. However, its cancer growth inhibitory effects and molecular mechanisms in human osteosarcoma cells have not been well and fully studied. Our previous proteomic study showed that DATS has the ability to suppress cell proliferation of Saos-2 cells by blocking cell cycle progression and inducing apoptosis in a dose-and timedependent manner. 25 In addition, DATS-sensitive proteins, including 18 downregulated proteins and nine upregulated proteins, were detected. Li et al 26 implied that DATS inhibited proliferation, invasion, and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating Notch-1 signaling. Wang et al 27 indicated that DATS induced osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway. However, the exact underlying molecular mechanisms are still unclear. Now the challenge is how to elucidate the antineoplastic mechanisms of DATS, which may be conducive to the development of chemotherapy for osteosarcoma. In this study, we aimed to observe the inhibitory effects of DATS on human osteosarcoma Saos-2 cells and to investigate the expression of GRP78 in osteosarcoma Saos-2 cells after they were treated with different concentrations of DATS for various time periods.
Materials and methods Materials
DATS (98% pure) was purchased from LKT Laboratories (Minneapolis, MN, USA). DMEM media and fetal bovine serum (FBS) were obtained from Gibco BRL (Grand Island, NY, USA). The rabbit anti-human polyclonal GRP78 antibody and mouse anti-human polyclonal β-actin were purchased from AbCam (Cambridge, UK). The fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit immunoglobulin G [IgG; heavy and light (H+L) chain] was obtained from EarthOx Life Sciences (Millbrae, CA, USA). HRPconjugated goat anti-rabbit and rat anti-mouse IgG were obtained from SCBT (Santa Cruz, CA, USA). Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and synthesized into cDNA using the PrimScript RT reagent kit (TaKaRa, Dalian, People's Republic of China). The Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA, USA). The primers were GRP78 forward: 5′-CGTCCTATGTCGCTTCACT-3′, reverse: 5′-TGTCTTTGTTTGCCCACCTC-3′.
cell culture
Human osteosarcoma Saos-2 cell lines were obtained from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, People's Republic of China). Cells were cultured in DMEM medium supplemented with 10% FBS at 37°C in humidified air containing 5% CO 2 . The cells were used in the logarithmic phase of growth throughout the experiment.
Immunofluorescent staining
Different concentrations of DATS (0, 25, 50, and 100 μM) were cultured for 24 h, and four time periods (24, 48, 72 , and 96 h) in the same concentration of DATS (50 μM). Saos-2 cells growing on 24-well culture plates were washed three times in PBS and fixed in PBS containing 4% formaldehyde for 30 min. Then the cells were washed twice in PBS and incubated for 30 min in 0.1% Triton X-100 in PBS. Next, the cells were blocked with 200 μL 10% normal goat serum (diluted with PBS) per well and incubated for 30 min at room temperature. Then, they were incubated with 200 μL primary anti-GRP78 antibody (dilution, 1:1,000) per well in a moist chamber at 4°C overnight. The cells were then washed three times with PBS and incubated with the goat anti-rabbit IgG/FITC antibody (dilution, 1:200) at room temperature for 30 min. Following this they were blocked with glycerol, followed by incubation with DAPI for 5 min at room temperature.
The samples were analyzed using a Leica DM4000B microscope (Leica Microsystems GmbH, Wetzlar, Germany), and images were captured using the Image Pro Plus image analysis system 7.0 (Media Cybernetics, Inc., Rockville, MD, USA) in order to detect the expression level. Cells in which the cytoplasm was stained green were considered to be GRP78 positive cells.
Quantitative real-time polymerase chain reaction (qrT-Pcr)
All qRT-PCRs were performed using SYBR Premix Ex Taq II (TaKaRa) and measured in a LightCyler 480 system (Roche, Basel, Switzerland). The levels of β-actin were used as an internal control. All of the reactions were run in triplicate. All data output from the qRT-PCR experiments were analyzed by using the 2 −ΔΔCT method (cells were cultured in the same way as mentioned in the "Immunofluorescent staining" section).
Western blot analysis
Protein was extracted from cell lines using RIPA buffer containing phenylmethanesulfonyl fluoride. A bicinchoninic acid protein assay kit (Beyotime, Haimen, People's Republic of China) was used to confirm the total protein concentration. Protein samples were separated by SDS-PAGE and transferred to polyvinyl membranes. Membranes were incubated overnight at 4°C with the primary anti-GRP78 antibody (dilution, 1:1,000), followed by the secondary antibody, HRP-conjugated goat anti-rabbit IgG (dilution, 1:20,000). The formula of the expression level of GRP78 protein was as follows: expression level of GRP78 protein = value of GRP78 protein in samples/value of β-actin in samples (cells were cultured in the same way as mentioned in the "Immunofluorescent staining" section).
Signals were observed by using a chemiluminescent detection kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The antibody against β-actin functioned as an internal reference. Typhoon PhosphorImager (GE Healthcare, Piscataway, NJ, USA) was used to measure the quality of the protein.
sirna and cell transfections
Saos-2 cells were grown to 70% confluence in 60-mm culture plates and washed twice with PBS. The cells were transfected for 48 h with 100 nM SMART pool siRNAs specific to non-targeting siRNA (scrambled siRNA) or GRP78 mRNA using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, MA, USA) in serum-free DMEM, according to the manufacturer's protocols.
MTT assay
Saos-2 cells were cultured in a 96-well culture plate with 5,000 cells/well. Cells were then exposed to scr-siRNA or GRP78-siRNA. The cells were treated with 50 μM DATS for 24 h, and then a cell survival assay was performed.
statistical analysis
The data were collected and shown as mean ± SD of at least three independent experiments. Statistical analysis was performed by one-way ANOVA followed by a post hoc comparison using the Bonferroni test. P,0.05 was considered to be statistically different.
Results
Immunofluorescent staining
GRP78 was mainly located in the endoplasmic reticulum (ER). Cells in which ER was stained green were considered to be GRP78 positive cells. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue). Fluorescence intensity of GRP78 in Saos-2 cells cultured in different concentrations of DATS for 24 h or in the same concentration of DATS (50 μM) for four time periods is shown in Figure 1 .
qrT-Pcr
GRP78 mRNA was identified in all samples. Relative expression of GRP78 mRNA in Saos-2 cells cultured in different concentrations of DATS for 24 h or in the same concentration of DATS (50 μM) for four time periods is shown in Figure 2 .
Western blot analysis
GRP78 protein was expressed in all samples. The relative intensity of GRP78 protein in Saos-2 cells cultured in different concentrations of DATS for 24 h or in the same concentration of DATS (50 μM) for four time periods is shown in Figure 3 .
grP78 silencing and cell proliferation
Before evaluating potential antiproliferative effects of DATS on cell proliferation, the efficiency of GRP78 silencing was verified by Western blot analysis, which demonstrated a significant reduction of GRP78 expression in cells transfected with GRP78-siRNA (Figure 4) . To assess the antiproliferative effects of DATS on cell proliferation, MTT assay was performed, and there were significant associations between GRP78 silencing and cell proliferation of DATS treatment (Figure 4 ). while research on the effect and mechanism of DATS against osteosarcoma was rare. Our previous study showed that DATS could induce cell apoptosis in a dose-and timedependent manner through regulating expression of some specific proteins. 25 In addition, a direct association between over-expression of GRP78 and osteosarcoma growth and metastasis came to light through our other previous study. 24 Therefore, we continued to conduct experimental studies in order to elucidate the mechanism and target of DATS on growth of human osteosarcoma on the basis of our previous research results.
In this study, we proposed and demonstrated the hypothesis, for the first time, that DATS could damage the normal structure of cells and inhibit the growth of osteosarcoma by downregulating expression of GRP78. Furthermore, our results showed that DATS downregulated the expression level of GRP78 in a dose-and time-dependent manner. Over-expression of GRP78 is known to correlate with the risk of tumor progression and metastasis, as reported in many articles. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Combining these reports and our previous results, we believed that DATS might inhibit the growth of osteosarcoma by downregulating expression of GRP78. We verified our hypothesis by a series of experiments such as qRT-PCR and Western blot. Our experimental results are consistent with our hypothesis, so we report, for the first time, that DATS can inhibit the growth of osteosarcoma cells by downregulating expression of GRP78. This is the possible mechanism and molecular target of DATS in the treatment of osteosarcoma. Therefore, downregulating expression of GRP78 with DATS treatment could be a possible therapeutic target for better management of osteosarcoma growth.
GRP78 is associated with tumor cell proliferation, apoptosis resistance, and metastasis, and plays an important role in the occurrence and apoptosis of tumors. 33 It can regulate several cancer-associated inflammatory cytokines, such as interleukin-6 (IL-6), 34 macrophage migration inhibitory factor (MIF), 35 transformed growth factor β (TGF-β), 36 and interleukin-10 (IL-10). 37 In addition, over-expression of GRP78 in poorly perfused solid tumors usually results from the ER stress pathway activated by glucose deprivation, hypoxia, and acidosis. 10 Therefore, downregulation or inhibition of GRP78 expression can promote apoptosis of tumor cells and prevent tumor growth and metastasis. Although some previous investigations found that DATS could inhibit the growth of osteosarcoma cells, the mechanism and target were not clear. Inspired by this, we conducted an in-depth study, in order to investigate the mechanism and target of DATS in the treatment of osteosarcoma cells.
In our experiment, the inhibitory effects on the cell growth curve and the morphological changes of Saos-2 cells were observed in a dose-and time-dependent manner after treatment with DATS. Simultaneously, the expression level of GRP78 was downregulated in a dose-and time-dependent manner. As previously stated, we have shown for the first time that DATS can inhibit the growth of osteosarcoma cells by downregulating expression of GRP78.
Conclusion
This study revealed the novel finding of the mechanism and molecular targets of DATS on the growth of osteosarcoma cells. These results indicate that DATS inhibits the growth of human osteosarcoma Saos-2 cells by downregulating expression of GRP78. The inhibitory effects of DATS on GRP78 expression of osteosarcoma cells provide a basis for the clinical use of DATS and supply a novel alternative 
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Zhang et al molecular target for the treatment of osteosarcoma. However, further in-depth preclinical experiments using relevant animal models are required.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
